JWH-139
JWH-139 is a synthetic cannabinoid that acts as a potent agonist at both the CB1 and CB2 receptors. It is part of the naphthoylindole family of compounds, which are known for their high affinity and selectivity for cannabinoid receptors. JWH-139 was developed by Dr. John W. Huffman and his team at Clemson University as part of their research into the structure-activity relationships of cannabinoids.
Chemical Structure and Properties[edit | edit source]
JWH-139 is chemically classified as a naphthoylindole, which is characterized by a naphthalene group attached to an indole core. The chemical formula for JWH-139 is C24H26O, and it has a molecular weight of 330.47 g/mol. The compound is typically synthesized through a series of organic reactions involving the condensation of naphthalene derivatives with indole moieties.
Pharmacology[edit | edit source]
JWH-139 exhibits high affinity for the CB1 and CB2 receptors, with a slight preference for the CB2 receptor. This selectivity makes it a valuable tool for studying the role of cannabinoid receptors in various physiological processes. The activation of CB1 receptors by JWH-139 is associated with psychoactive effects, while CB2 receptor activation is linked to anti-inflammatory and immunomodulatory effects.
Legal Status[edit | edit source]
The legal status of JWH-139 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. Researchers must obtain special licenses to study JWH-139 and similar synthetic cannabinoids.
Research Applications[edit | edit source]
JWH-139 is primarily used in scientific research to explore the effects of cannabinoid receptor activation. Studies have investigated its potential therapeutic applications, including pain management, neuroprotection, and anti-inflammatory effects. However, due to its psychoactive properties, its use in clinical settings is limited.
Safety and Toxicology[edit | edit source]
The safety profile of JWH-139 is not well-established, as it is primarily used in laboratory settings. Like other synthetic cannabinoids, it may pose risks of adverse effects, including anxiety, tachycardia, and hallucinations. Long-term effects are not well understood, and caution is advised when handling this compound.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD